- Breast-conserving therapy for breast cancer
- The effect of radiation in patients with BRCA-1 or BRCA-2 mutations
- The use of intensity modulated radiotherapy in the treatment of breast cancer
- Indications for post-mastectomy radiotherapy
- The use of radiosensitizers in patients with refractory disease
Dr. Lori Pierce attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD from 1990-1992. In 1992, Dr. Pierce joined the faculty of the University of Michigan where she is currently Professor with tenure in Radiation Oncology. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs, a position she still holds.
Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists’ Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board.
Dr. Pierce has published over 200 manuscripts and book chapters and has received numerous teaching awards from the University of Michigan and multiple national organizations. Honors include receipt of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists’ Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. Dr. Pierce was elected to the National Academy of Medicine, Class of 2018. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. Most Recently, she was the recipient of the 2021 Association of Community Cancer Centers Annual Achievement Award and the 2021 American Society for Radiation Oncology Gold Medal Award. In 2018, she was elected president-elect of the American Society of Clinical Oncology, the largest organization of oncology professionals in the world, and served as president in 2020-2021. She is currently Chair of the Board.
Areas of Interest
- Breast cancer
Honors & Awards
2019-23 ASCO President-elect, President, Chair of the Board, Past-President
2019 Woman of the Year Award, United Way of Washtenaw County
2018 National Academy of Medicine member
2018 Zeta Phi Beta Sorority, Inc., Platinum & Pearls Gala, Community Award
2018 Hologic Inc, Endowed Women Who Conquer Cancer Mentorship
2017 MICHR Distinguished Clinical and Translational Research Mentor Award
2017-19 Castle Connolly’s Exceptional Women in Medicine
2017 Robert E. Guenzel Award, United Way of Washtenaw County
2013-19 Castle Connolly’s America’s Top Physicians for Cancer
2015 Malcolm Bagshaw Visiting Professor, Stanford University
2015 Fellow Inductee, American Society for Clinical Oncology (ASCO)
2013-17 Listed among Castle Connolly’s “America’s Top Physicians for Cancer”
2013 AAWR Marie Curie Award
2013 League of Educational Excellence Award
2010-18 Susan G. Komen for the Cure Scholar
2010-19 Member of Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Steering Committee
2010 Sara Goddard Power Award from the American Women’s Caucus
2010 Fellow Inductee, American Society for Radiation Oncology (ASTRO)
2007 AMA Women Physician Mentor Award
2002 Lifetime Achievement Award, Sister’s Network, Inc.
1999 Included in Good Housekeeping’s “Best Doctors for Breast, Lung and Colorectal Cancer”
1998-17 Listed among Castle Connolly’s “America’s Top Doctors for Breast Cancer”
1995 ESTRO Travel Award
1995-98 American Cancer Society Clinical Oncology Career Development Award
- MD, Duke University, 1985
- Residency, University of Pennsylvania, Radiation Oncology, 1986-89
- Chief Resident, University of Pennsylvania, 1988-89
- Board Certification: Radiation Oncology
- (PI: Pierce), 10/1/15– 9/30/19, Breast Cancer Research Foundation: Breast Cancer Cell Sensitivity to Radiotherapy in the Presence of Targeted Therapies and Predictors of Early vs. Late Response, Role: Principal Investigator.
- (PI:Pierce), 2/1/11 – 1/31/20, Michigan Blue Cross Blue Shield: The Michigan Radiation Oncology Quality Consortium, Role: Principal Investigator, Director.
Selected from 164 publications
- Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M, Haffty B, Ben-David M, Kaufman B, Merajver S, Balmaña J, Kierovitz A, Domchek S. Local therapy in BRCA1 and BRCA 2 mutation carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Br Can Res Treat. 121(2):389-398, 2010. PMC2936479.
- Speers C, Zhao S, Liu M, Bartelink H, Pierce LJ, Feng F. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Can Res. 21(16):3667-77, 2015. doi:10.1158/1078-0432.CCR-14-2898. PMID:25904749
- Jagsi R, Griffith K, Hayman J, Boike T, Walker E, Nurushev T, Grills I, Moran J, Feng M, Hayman J, Pierce LJ. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: Comparative analysis of physician-assesses and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 1(7):918-930, 2015. PMID:26247417
- Pierce L, Feng M, Griffith K, Jagsi R, Boike T, Dryden D, Gustafson G, Benedetti L, Matuszak M, Nurushev T, Haywood J, Radawski J, Speers C, Walker E, Hayman J, Moran J on behalf of MROQC, the Michigan Radiation Oncology Quality Consortium. Recent time trends and predictors of heart dose from breast radiotherapy in a large quality consortium of radiation oncology practices. Int J Rad Onc Biol Phys, 99(5);1154-1161,2017. Jul 22. pii: S0360-3016(17)33606-4. doi: 10.1016/j.ijrobp.2017.07.022. PMID: 28927756.
- Jagsi R, Griffith K, Bellon J, Woodward W, Horton J, Ho A, Feng F, Speers C, Hayes D, Overmoyer B, Sabel M, Schott A, Pierce L. Concurrent veliparib with chest-wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: The TBCRC 024 Phase 1 Multicenter Study. J Clin Oncol, 2018. doi: 10.1200/JCO.2017.77.2665. PMID:29558281.
- Jagsi R, Griffith K, Moran J, Ficaro E. March R, Dess R, Chung E, Liss A, Hayman J, Mayo C, Flaherty K, Corbett J, Pierce L. A randomized comparison of radiation therapy techniques in the management of node-positive breast cancer: Primary outcomes analysis. Int J Rad Onc Biol Phys: 101(5); 1149-1158, 2018. PMID:30012527